The hormone receptor (HR)-positive breast cancer accounts for 60–75% of all cases (1, 2), which always shows a favorable prognosis with adjuvant endocrine therapy and might avoid the cytotoxicity of chemotherapy. This evidence concerns the gene NR4A1 and breast cancer.